FRANK LAFAZIA: Open Payments
NPI 1659377307 · WEST WARWICK, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,101 in 221 payments from 25 companies in 2025. Trend: 2023 $3,839 · 2024 $4,010 · 2025 $4,101
Food & beverage: $4,101
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 24 | $456 |
| ABBVIE INC. | 16 | $366 |
| GlaxoSmithKline, LLC. | 19 | $322 |
| E.R. Squibb & Sons, L.L.C. | 21 | $321 |
| AstraZeneca Pharmaceuticals LP | 13 | $290 |
| Lundbeck LLC | 13 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $236 |
| Lilly USA, LLC | 11 | $222 |
| Otsuka America Pharmaceutical, Inc. | 11 | $183 |
| Exact Sciences Corporation | 6 | $153 |
Products named: REXULTI, TRELEGY ELLIPTA, TRINTELLIX, VRAYLAR, MOUNJARO, Wegovy, Rybelsus, AIRSUPRA.
Industry payments across RI — which companies pay providers there.
